Pathology Of Explanted Cryopreserved Allograft Heart Valves: Comparison With Aortic Valves From Orthotopic Heart Transplants  by Mitchell, Richard N. et al.
PATHOLOGY OF EXPLANTED CRYOPRESERVED ALLOGRAFT HEART VALVES: COMPARISON
WITH AORTIC VALVES FROM ORTHOTOPIC HEART TRANSPLANTS
Richard N. Mitchell, MD, PhDa
Richard A. Jonas, MDb
Frederick J. Schoen, MD, PhDa
Objective: We sought to determine the morphology, mechanisms of deteri-
oration, cellular viability, extracellular matrix integrity, and the role of
immune responses in the dysfunction of cryopreserved aortic and pulmonic
valve allografts. Methods: We studied 33 explanted left-sided (n 5 20) or
right-sided (n 5 13) cryopreserved human allograft heart valves explanted
several hours to 9 years after operation, 14 nonimplanted allografts, and 16
aortic valves removed from transplanted allograft hearts 2 days to 4 years
after operation. Analysis included gross inspection, radiography, light
microscopy, electron microscopy, and immunohistochemical studies. Re-
sults: Allografts implanted for more than 1 day had progressive collagen
hyalinization and loss of normal structural complexity and cellularity,
including endothelium and deep connective tissue cells. Inflammatory cells
were generally minimal or absent in the allografts. Transmission electron
microscopy of long-term cryopreserved allograft valves revealed no viable
cells, focal calcification centered around dead cell remnants, and distorted
but preserved collagen. In contrast, aortic valves from transplanted hearts
showed remarkable structural preservation, including endothelium and
abundant deep connective tissue cells; inflammatory infiltrates were gen-
erally mild and of no apparent deleterious consequence, including valves
from patients who died of fatal rejection. Conclusions: Cryopreserved
allografts are morphologically nonviable; their collagen is flattened but
largely preserved. They are unlikely to grow, remodel, or exhibit active
metabolic functions, and their usual degeneration cannot be attributed to
immunologic responses. In contrast, aortic valves of transplanted hearts
maintain near-normal overall architecture and cellularity and do not show
apparent immunologic injury, even in the setting of fatal myocardial
parenchymal rejection or graft arteriosclerosis. (J Thorac Cardiovasc Surg
1998;115:118-27)
Aortic or pulmonic valve allografts have excep-tionally good hemodynamic profiles, a low inci-
dence of thromboembolic complications without
anticoagulation, and resistance to endocarditis.1-4
Although allograft valves were initially collected by
sterile technique and were used fresh, logistic real-
ities necessitated the use of antibiotic treatment or
preservation. The most common preservation
method (cryopreservation) involves freezing in di-
methyl sulfoxide and storage with liquid nitrogen.
The durability of contemporary cryopreserved allo-
graft valves is equal to or slightly better than that of
conventional porcine bioprosthetic valves (50% to
90% allograft survival at 10 to 15 years).4-6
Nevertheless, important questions remain: (1)
Are viable donor cells, including intrinsic cuspal
interstitial tissue cells and endothelial cells, present
at the time of implantation of cryopreserved allo-
graft valves and do they persist over the long term?
(2) Does long-term function require donor cell
viability or just the intrinsic extracellular matrix? (3)
To what extent is valve degeneration attributable to
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immune responses? To elucidate these issues, we
evaluated explanted cryopreserved allograft valves
and compared them with aortic valves recovered
from short-term and long-term heart transplants.
Materials and methods
We examined 33 explanted human cryopreserved allo-
graft valves in place several hours to 9 years (11 for more
than 3 years), 14 thawed but unused cryopreserved valves,
and 16 aortic valves removed from orthotopic heart
transplants (Tables I and II).
Of the cryopreserved allograft valve explants, 12 were
aortic valves/root replacements (recipient age, 4 to 57
years; seven recipients older than 10 years of age) and 13
were right ventricle–pulmonary artery conduits (recipient
age, 1 week to 44 years; 11 recipients 10 years old or less);
donor ages were 2 months to 41 years. Explanted primar-
ily because of structural deterioration, growth-related
stenosis, or infection, these valves were derived from a
clinical investigation by a consortium of five tissue banks
in the United States performed under an Investigational
Device Exemption issued by the Food and Drug Admin-
istration (24 explants) and from the surgical practice of
one of us (R.A.J.) using commercial valves.9
The 16 aortic valves from heart transplants were re-
moved at autopsy (15 specimens during 1984 through
1991, fixed 41 minutes to 24 hours after death) or retrans-
plantation (one, fixed within 1 hour), recovered days to 4
years after transplantation, after myocardial rejection
(n 5 4), graft coronary arteriosclerosis (n 5 4), and other
causes (n 5 8) (Table II). Transplant patients received
standard triple-drug immunosuppression (prednisone, cy-
closporine A [INN: ciclosporin], and azathioprine), with
occasional bolus methylprednisolone sodium succinate
(Solu-Medrol) or antilymphocyte antibody treatment for
acute rejection episodes, as shown in Table II.
Valves were fixed in 10% neutral buffered formalin;
cryopreserved allograft valves (n 5 5) for electron micros-
copy were fixed in 2.5% glutaraldehyde, 2% paraformal-
dehyde, and cacodylate buffer, pH 7.4. Analysis included
radiography and light microscopy (stains: hematoxylin and
eosin [overall morphology], Masson’s trichrome [colla-
gen], Movat pentachrome [elastin and other connective
tissue elements], and von Kossa [calcification]).
Immunohistochemical studies identified endothelial
cells (CD31 or von Willebrand’s factor) and T- and
B-lymphocyte subsets (CD45RO/UHCL-1 and CD20/L26,
respectively); one valve was stained for vimentin interme-
Table I. Cryopreserved aortic and pulmonic
allograft valves (n 5 33)*
Duration Cause of failure
Aortic position
0 days (7) Technical/defective valve
1 day (2) Sepsis (died)
2 days (2) Dehiscence (died)
3 days Uncertain
4 days Congestive heart failure/stenosis
5 days Insufficiency
2-4 mo (3) Infective endocarditis




8 days Multisystem failure
6 mo (2) Stenosis
16 mo Stenosis
3-6 yr (5) Stenosis
7-9 yr (4) Stenosis
*No immunosuppressive therapy; 14 additional cryopreserved/thawed
valves used as controls.
















14 days Rejection 1 Methylprednisolone,
OKT3 2 days before
death
24 days Pneumonia 0 —
25 days (2) Mycotic aneu-
rysm
0
Ischemic injury 0 —
37 days Rejection 1 Methylprednisolone,
13 days before death
2 mo Lymphoma 0 Methylprednisolone,
antithymocyte globu-









7.5 mo Rejection 12 Methylprednisolone,
16 days before death
10 mo (3) Rejection 1 Methylprednisolone,

















*Standard triple-drug maintenance immunosuppression (prednisone, cy-
closporine A, azathioprine).
†International Society for Heart and Lung Transplantation grade 3 or
greater, per Billingham ME, Cary NRB, Hammond EH, Kemnitz J,
Marboe C, McAllister HA, et al. A working formulation for the standard-
ization of nomeclature in the diagnosis of heart and lung rejection: heart
rejection study group. J Heart Transplant 1990;9:587-93.
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diate filaments and smooth muscle cells (HHF 35). All
antibodies were from Becton-Dickinson (Bedford, Mass.).
Results
Morphologic results are summarized in Figs. 1 to
6 and Table III. Results from aortic and pulmonic
site explants and pediatric and adult recipients were
identical, except where indicated.
Progression of cuspal and aortic/pulmonic wall
changes in cryopreserved allograft valves
Unimplanted valves. Unimplanted cryopreserved
and thawed allograft valves retained normal trilam-
inar architecture, but there was mild autolysis with
smudging of the collagenous substructure, mild loss
of amorphous extracellular matrix, and variable
nuclear pyknosis of interstitial cells (Fig. 1, A).
Elastic tissue appeared intact. Endothelial cells were
focally and variably demonstrable (Fig. 6, A). Mono-
nuclear inflammatory cells were usually minimally
present (Fig. 6, B).
Short-term explants (1 to 8 days). Cryopreserved
allograft valves implanted up to 8 days showed
further autolysis and structural deterioration with
progressive loss of interlayer demarcations, flatten-
ing of the normal outflow surface corrugations, and
variably but occasionally markedly diminished inter-
stitial tissue cells, near-complete loss of endothelial
cells, and generally trivial T-lymphocytic infiltrate,
without neutrophils (Fig. 1, B). Many had cuspal
hematomas or superficial mural thrombi.
Intermediate-term explants (2 to 11 months). In
valves implanted 2 to 11 months, there was marked
deterioration of structural detail and fragmented
elastic tissue with reduced staining. Cusps were
flattened and thinned, with virtually no stainable
interstitial tissue cells. Inflammatory cells, including
neutrophils, macrophages, and T-lymphocytes, were
prominent only in infective endocarditis.
Long-term explants (1 to 9 years). Gross and ra-
diographic features of long-term cryopreserved al-
lograft valves are illustrated in Fig. 2; histologic
details are summarized in Fig. 3. Valves implanted
over 1 year had flattened and thinned cusps with
obliteration of the usual corrugations, indistinct
layers, and no stainable interstitial or endothelial
cells (Fig. 3, A and B). Pannus overgrowth was
generally mild and was clinically important in none.
Residual elastin was present but diminished (Fig. 3,
C). One long-term valve had an area of noninflam-
matory, vimentin-positive cells in the mid-cusp area
(Fig. 3, D), consistent with fibroblasts (Fig. 6, C),
and a superficial smooth muscle actin-positive cell
layer, suggesting origin from pannus. Lymphocytes
and other inflammatory cells were sparse. Cuspal
Fig. 1. Unimplanted valve and short-term explant: photomicrographs of valve cusps. A, Unimplanted
valve. B, Valve removed at autopsy 2 days after implantation. Insets show corresponding low-power
photomicrographs. Although the explanted valve retains a layered architecture, its interstitial cellularity is
substantially diminished, and the outflow surface is flattened and less rippled than normal, suggesting early
stretching of collagen toward a configuration characteristic of diastole. (Hematoxylin and eosin stain,
original magnification 1753; insets 903.)
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hematomas and mural thrombi were variable; cuspal
calcification (occasionally nodular [Fig. 3, G]), was
only focally present, despite extensive wall calcifica-
tion in some explants, especially in stenotic right
ventricular–pulmonary artery conduits from chil-
dren.
Aortic and pulmonic wall portions of cryopre-
served allograft valves generally had intact elastic
lamellae but progressive loss of nuclear staining;
endothelial cells were largely absent by 2 days, and
extensive medial necrosis was observed as early as 3
days after implantation (Fig. 3, E). Wall calcification
was variable, with occasional large nodular deposits,
focal deposits suggesting cell association, and fre-
quently prominent linear deposits involving elastin
(Fig. 3, F).
Transmission electron microscopy of long-term
valve cusps and walls demonstrated abundant de-
generated interstitial tissue cells (Fig. 4, A) and focal
microcalcifications, largely associated with cell
membranes and organelles. Cuspal collagen bundles
persisted but had lost their natural crimp and were
markedly flattened (Fig. 4, B).
Aortic valves from orthotopic heart transplants.
In contrast to the markedly abnormal structure of
cryopreserved allograft valves, aortic valves from
long-term cardiac transplants had essentially nor-
mal trilaminar structure, cuspal corrugations, nor-
mal and well-preserved extracellular matrices, in-
terstitial and endothelial cells, and neither cuspal
hematomas, mural thrombi, nor calcifications
(Fig. 5). Mononuclear inflammatory cell infil-
trates, composed primarily of T-lymphocytes,
were diffuse but not prominent in most valves and
were generally comparable with those seen in
nonimplanted valves (Fig. 6, B). There were no
Fig. 2. Long-term explants, gross photographs, and radiographs. A, Pulmonic valve allograft and pulmo-
nary artery conduit removed after 9 years for root stenosis from a child with repaired congenital heart
disease. B, Radiograph of valve and conduit shown in A. Despite diffuse nodular mineralization of the
pulmonary artery conduit wall, the cusps were soft, pliable, and noncalcified. C, Aortic allograft valve
removed for aortic stenosis 4.7 years after the operation. D, Radiograph of valve shown in C; nodular
cuspal calcification is evident. E, Aortic valve allograft removed after 3 years for aortic insufficiency
resulting from cuspal prolapse. No calcification was noted.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 1
Mitchell, Jonas, Schoen 1 2 1
differences in valves from allografts failing as a
result of severe parenchymal rejection or graft
arteriosclerosis regardless of immunosuppression
regimens (Fig. 6, D to G) nor in valves from
allografts having as many as 12 rejection episodes.
Significantly, these results suggest no valvular
destruction or any other deleterious morphologic
effect resulting from inflammation.
Discussion
This study documents and extends our prelimi-
nary data on the morphologic features of explanted
cryopreserved aortic and pulmonic valves7, 8 and
includes comparisons with aortic valves obtained
from orthotopic heart transplants.
Cellular viability. A theoretic advantage of cryo-
preserved allograft valves over glutaraldehyde-fixed
Fig. 3. Long-term explants: photomicrographs of cusps and aortic wall. A, Cusp from right-sided valve
explanted after 7 years. B, Aortic valve explanted after 5 years. Insets show low-power view of the same valves.
A and B show overall flattening and loss of normal layered architecture, as well as loss of endothelial and deep
interstitial cells. In A, a cuspal hematoma/thrombus is present at the lower (inflow) surface (arrow). C and D,
Aortic valve explanted after 3 years. In C, the remnant layered architecture is highlighted by the staining for
elastin (arrow). In C and D there is patchy cuspal interstitial cellularity. A representative stained cell nucleus is
highlighted by an arrow in D. E, Aortic wall remnant of valve shown in B, demonstrating replacement of normal
aortic wall architecture by fibrosis. F, Nodular calcification of aortic wall portion of right-sided pulmonic valve
and pulmonary artery allograft, with prominent calcification along the residual pulmonary artery elastin (arrow).
G, Cuspal calcific nodules (arrows). A, B, D, and E, Hematoxylin and eosin stain; F and G, Stained with von
Kossa’s reagent (calcium phosphates are black). Magnifications: A, B, inset D, E, and F, original magnifications
1753; inset A, B, C, and D, 903. C, Stained with Movat pentachrome stain (elastin black).
The Journal of Thoracic and
Cardiovascular Surgery
January 1998
1 2 2 Mitchell, Jonas, Schoen
bioprostheses is maintenance of interstitial and en-
dothelial cell viability, potentially enabling continu-
ous remodeling, growth, and thromboresistance.
However, consistent with other recent studies,9, 10
our results document a consistent and marked pau-
city of viable cuspal cells in cryopreserved allograft
valves implanted for any time over 2 months. Al-
though the presence of nuclear staining does not
necessarily prove that cells are viable or healthy,
absence of nuclear staining by routine histologic
examination or fragmentation observed by electron
microscopy is generally construed to indicate ab-
sence or death of preexisting cells.
The lack of viable cells reflects the cumulative
damage of ischemia before and after harvest, cryo-
preservation, thawing, and implantation trauma. Al-
though cell injury during ischemia and cryopreser-
vation of allograft valves is well documented,11, 12
some workers report long-term survival of certain
cellular elements in both experimental systems and
explanted allografts from human recipients.2, 13-15 In
one study, viable fibroblasts were routinely cultured
from explanted cryopreserved allografts.2 Some of
these may derive from recipient pannus, as our
identification of vimentin and smooth-muscle actin-
positive cells in one long-term implant suggests.
Nevertheless, the finding by chromosomal analysis
of donor-derived fibroblasts cultured from one cryo-
preserved allograft after 9 years indicates that occa-
sional donor fibroblasts may survive and possibly
proliferate in some optimally preserved valves (i.e.,
minimal ischemia and cryopreservation-induced
damage).2 However, it is unlikely that a limited
population of viable cells will contribute to anatom-
ically appropriate cellularity capable of functional
matrix remodeling.
Allograft valve durability: Role of collagen and
calcification. The absence of donor valve fibroblasts
capable of contributing to remodeling of the extra-
cellular matrix implies that durability of the cryo-
preserved allograft valve is dependent predomi-
nantly on the quality of the original collagenous
skeleton. Indeed, ongoing degeneration of the ex-
tracellular matrix likely accounts for the modest rate
of progressive dysfunction (predominantly regurgi-
tation) in the aortic site in adults. Our ultrastruc-
tural results suggest that the collagen network de-
rived from the donor valve is largely intact, thereby
providing the structural basis for long-term perfor-
mance. It follows that modest delays from donor
death to graft harvest may have little effect on this
relatively autolysis-resistant collagenous skeleton.
Indeed, allografts implanted in sheep showed no
functional or pathologic differences among valves
Fig. 4. Long-term explants; ultrastructure. A, Cellular remnants (open arrows) with focal microcalcification
(solid arrow) are present diffusely throughout the cuspal connective tissue matrix, despite the absence of
cellular staining on routine histologic stains. B, Dense residual collagen (c) and cell remnants (arrow) in
long-term explant. The collagen has some degradation of structure and marked flattening characteristic of
the diastolic configuration; wavy crimp typical of a relaxed normal valve is absent. Stained with uranyl
acetate and lead citrate. Double-headed arrow in lower left 5 3 mm. Original magnification 10,0003.
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removed up to 48 hours post mortem from sheep
cadavers maintained at 4° C16 and between cryopre-
served and fresh antibiotic-treated valves preserved
at 4° C for up to 6 days.17 This suggests possible
expansion of the donor pool for allografts by extend-
ing current limits on postmortem interval.
Calcification in cryopreserved allograft valves was
most prominent in the pulmonary arterial or aortic
walls, consistent with prior studies showing extensive
wall calcification as a major failure mode for cryo-
preserved allograft valves in the pulmonary circula-
tion of children18; cuspal calcification was substan-
tially less frequent. As with other cardiovascular
calcification processes,19, 20 deposits appeared to
originate in residual nonviable cells, their fragments,
elastic tissue, or collagen. The reason(s) for less
calcification of cryopreserved allograft valves rela-
tive to glutaraldehyde-fixed porcine bioprosthetic
valve cusps is uncertain. We hypothesize that allo-
graft valves have more extensive autolysis during
processing, intraoperative preparation, and possibly
after implantation, and that autolysis may reduce
the calcifiability of the residual cellular debris.
Contribution of the immune response to allograft
deterioration. Although cryopreserved allograft
valves may induce a detectable donor HLA-specific
humoral response21-23 and may be associated with
unexplained postoperative fever,24 there is no evi-
dence that these reactions contribute to valve dis-
ease. Progressive loss of cuspal cellular viability and
cumulative changes in the extracellular matrix oc-
curred in the absence of significant mononuclear
inflammatory cell infiltrates, despite lack of immu-
nosuppression and unmatched HLA or blood
groups. Neutrophilic infiltrates, anticipated for an-
tibody-mediated injury, were also notably absent.
Significant inflammation was seen only in endocar-
ditis. Thus our results provide no evidence that
cell-mediated immune injury causes pathologic
changes in the cryopreserved allograft valve; indeed,
they suggest that immune responses are noncontrib-
utory. Inasmuch as cryopreserved allograft valves
were examined at many postoperative intervals,
including the first week (during which significant
histologic deterioration occurs), transient occult im-
mune injury is unlikely. However, it remains possi-
Fig. 5. Photomicrographs of cusps from valves from orthotopic heart transplants. A, Aortic valve removed
from patient dying of fulminant acute myocardial rejection 7.5 months after the operation. This patient had
had 12 treatable rejection episodes over 7 months; the last augmentation of immunosuppression was with
methylprednisolone sodium succinate (Solu-Medrol) 16 days before death. B, Aortic valve removed from
patient dying of graft coronary arteriosclerosis 4 years after heart transplantation; last augmentation of
immunosuppression was with methylprednisolone 4 months before death. Both valves show the expected
layered architecture outflow surface rippling characteristic of the normal valve in the relaxed state, as well
as a normal complement of interstitial and endothelial cells. (Hematoxylin and eosin, original magnifica-
tions 903.)
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Fig. 6. Immunohistochemical staining results. A, Von Willebrand’s factor staining of unimplanted cusp
demonstrating sparse preservation of endothelial cells. B, CD45RO immunohistochemical staining of unim-
planted valve demonstrating a mild diffuse infiltrate of mononuclear inflammatory cells (T-lymphocytes and
macrophages). C, Immunohistochemical staining of valve cusp shown in Fig. 2, C and D for vimentin showing
positivity of interstitial cells near the inflow surface, suggesting that these are mesenchymal cells derived from
recipient pannus formation. D, T-cell (CD45RO) staining of valve removed from heart transplant patient who
died of a technical complication 2 days after the operation. E, T-cell (CD45RO) staining of aortic valve from
heart transplant patient dying 2.5 months after the operation of complications of perioperative myocardial
ischemic injury. F, T-cell (CD45RO) staining of aortic valve of heart transplant from patient who required
retransplantation 6.5 months after transplantation for graft coronary arteriosclerosis. G, T-cell (CD45RO)
staining of aortic valve from heart transplant patient who died 7.5 months after the operation of fulminant acute
myocardial rejection (also shown in Fig. 5, A). H, T-cell (CD45RO) staining of myocardium from heart whose
aortic valve is represented in G. These immunohistochemical studies demonstrate that T-cells are sparse in
aortic valves of heart transplants in the early postoperative period and although present in greater density
thereafter do not appear to correlate with myocardial infiltrates in acute myocardial rejection. Despite the
presence of T-cell infiltrates in the valve from a heart necessitating retransplantation for graft arteriosclerosis
(F), there is no evidence of intimal proliferation characteristic of the coronary arterial lesion (see Fig. 5, B). (All
original magnifications 1753.)
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ble that immunologically mediated injury occurred
undetected in the temporal window between 9 days
and 2 months after implantation (specimens un-
available).23
The lack of morphologic evidence of immune-
mediated injury has several implications. Foremost,
these data suggest no rational basis for the use of
immunosuppression in improving the durability of
cryopreserved allograft valves. Inasmuch as endo-
thelial cells, smooth muscle cells, and fibroblasts are
in fact variably capable of eliciting an immune
response,25-27 the lack of immune injury may be
attributable in part to loss of cell viability. Indeed,
immunologic reactivity and allograft valve durability
are affected by preservation methods.28, 29 However,
the absence of immune-mediated pathologic
changes even in viable valves from heart transplants
suggests an intrinsic resistance to immune injury
(see below).
Aortic valves from orthotopic heart transplants.
The present study shows that aortic valves from both
short-term and long-term heart transplants have
essentially normal gross and microscopic structure
and intrinsic cellularity, in agreement with another
recent report.30 The valves we studied included
those from patients with as many as 12 previous
rejection episodes and from fatal myocardial rejec-
tion in which the allograft response had over-
whelmed immunosuppression. Valves from trans-
plants were also free of degenerative features,
including calcification and the intimal thickening
characteristic of graft arteriosclerosis. Moreover,
the mild T-lymphocytic infiltrate seen in valves from
allograft hearts was comparable with that in normal
aortic valves removed at autopsy (i.e., unimplanted
cryopreserved allograft valves in this study).
It is uncertain why valves in heart transplants are not
apparently damaged by rejection. We hypothesize
several possible factors: (1) the endothelium overlying
valves has a different level of histocompatibility and
adhesion molecule expression than that of the myo-
cardial microvasculature or (2) high flow over the valve
surface (relative to slower flow within the myocar-
dium) reduces significant mononuclear inflammatory
cell binding. Moreover, with significantly lower meta-
bolic demand than myocardium, valves in heart trans-
plants should have less ischemic injury during trans-
plantation with consequently less ischemia-induced
up-regulation of adhesion molecules.
Conclusions
Cryopreserved allograft heart valves have early
cellular autolysis and exhibit severe degeneration
after implantation, with disruption of normal archi-
tectural detail, loss of endothelial and interstitial
cells, and variable mild inflammatory cellularity.
They are unlikely to have any significant capacity to
grow, remodel, or exhibit active metabolic functions.
Their durability seems primarily related to the
largely preserved extracellular matrix. That 33 ex-
planted cryopreserved allograft valves deriving from
five different tissue banks and one commercial
source showed similar results suggests that our
results are broadly representative. In contrast, aortic
valves of transplanted hearts maintain near-normal
overall architecture and cellularity. No evidence for
immune-mediated dysfunction was found in either
type of aortic valve allograft.
Table III. Morphology of allograft cardiac valves
Cryopreserved
Cardiac transplant:
0 days–4 yrUnimplanted 0-8 days 2-11 mo 1-9 yr
Number of specimens 14 15 6 12 16
Trilaminar architecture 11 11 2 2 111
Stainable connective tissue cells 11 1/11 2 2 to 1† 111
Lymphocytic infiltrate (T-cells) 2 to 1 2/1 2 to 111* 2 to 1 1/11
Intact endothelium 2/1 2/1 2 2 1/11
Intimal hyperplasia/pannus 2 2 2 1/2 2
Cuspal hematoma/thrombus 2 2/1 1/11 2 to 11 2
Calcification
Cusps 2 2 2 2 to 1 2
Walls 2 2 2 2 to 111 2/1
Cellularity and other morphologic measures of the explanted valves semi-quantified as: 2 5 not present; 1 5 mild/minimal; 11 5 moderate; and 111
5 severe/marked.
*Substantial only in those valves with endocarditis.
†Predominantly associated with pannus.
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